Checkpoint Therapeutics Inc CKPT.OQ CKPT.O is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024
The Waltham Massachusetts-based company is expected to report a 66.7% decrease in revenue to $10.33 thousand from $31 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Checkpoint Therapeutics Inc is for a loss of 15 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Checkpoint Therapeutics Inc is $20.00, above its last closing price of $3.46.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.30 | -0.30 | -0.18 | Beat | 41 |
Mar. 31 2024 | -0.29 | -0.27 | -0.33 | Missed | -20.7 |
Dec. 31 2023 | -0.54 | -1.10 | Missed | -102.5 | |
Sep. 30 2023 | -0.75 | -0.76 | -0.29 | Beat | 61.8 |
Jun. 30 2023 | -0.77 | -0.78 | -1.05 | Missed | -34.6 |
Mar. 31 2023 | -1.09 | -1.07 | -0.89 | Beat | 16.6 |
Dec. 31 2022 | -1.30 | -1.31 | -2.29 | Missed | -75.3 |
Sep. 30 2022 | -1.47 | -1.47 | -1.20 | Beat | 18.2 |
This summary was machine generated November 8 at 21:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments